Collaboration leads to better digital healthcare solutions
Wellthy Therapeutics, a leading digital therapeutics (DTx) company has partnered with Bayer, one of the leading enterprises with core competencies in the Life Science fields of health care. Through this partnership, Bayer’s G4A team will going to strengthen its latter’s product, regulatory and commercialization capabilities while exploring areas of collaboration. Bayer and Wellthy Therapeutics have already introduced digital health care solution to worldwide and disease management platform to the patients.
Introduce digital therapeutics to patients worldwide
Bayer is a global enterprise in the healthcare and agriculture situated over in 34 countries. The company performs its social and ethical responsibilities as a corporate citizen. Bayer analyses DTx in the categories like health care, delivering evidence-based therapeutic interventions built with high quality software programs to prevent, manage, or treat specific chronic conditions.
Advancements in digital therapeutics over the last few years have been enabling an integrated health approach for and with the patients. Bayer has been specifically tracking Wellthy Therapeutics for some time, and is particularly delighted to have them on board. “We look forward to supporting the advancement of their patient centric, outcomes focused approach to care, and explore opportunities to collaborate”, says Global Head of Bayer G4A Digital Health.
Forming partners to enhance patient’s health
Wellthy Therapeutics is on mission to improve patients’ health and prevent to manage their chronic condition. It is taking efforts on providing health care solutions like mono therapy with combination of pharmaco therapy, Diabetes and Cardiology. To improve patient’s health, the company has been forming partnerships with health care systems, pharmaceutical companies and medical device companies.
“We are humbled and excited to begin this journey with Bayer, to improve our product, strengthen our company and develop goes to market solutions that accelerate our journey to bring digital therapeutics to patients worldwide,” Wellthy Therapeutics CEO and Co-Founder Abhishek Shah said
